Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes

Bibliographic Details
Main Authors:	Doehner, H, Vyas, P, Seymour, JF, Santini, V, Stone, RM, Minden, MD, Al-Ali, HK, del Castillo, T, Morrill, J, Songer, S, Weaver, J, Skikne, BS, Beach, CL, Dombret, H
Format:	Conference item
Published:	Elsevier 2017

Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)
by: Doehner, H, et al.
Published: (2016)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
by: Döhner, H, et al.
Published: (2018)

P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE
by: A. H. Wei, et al.
Published: (2022-06-01)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
by: Lisa Pleyer, et al.
Published: (2017-02-01)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
by: Farhad Ravandi, et al.
Published: (2021-08-01)

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
by: Daniel Lopes De Menezes, et al.
Published: (2023-08-01)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
by: John F. Seymour, et al.
Published: (2017-12-01)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
by: DiNardo, C, et al.
Published: (2019)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
by: Etienne Sollier, et al.
Published: (2023-08-01)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
by: Esther Natalie Oliva, et al.
Published: (2023-04-01)

P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
by: S. Garciaz, et al.
Published: (2022-06-01)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
by: Hong Pan, et al.
Published: (2023-08-01)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
by: António Almeida, et al.
Published: (2017-01-01)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
by: N. Daver, et al.
Published: (2022-06-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
by: Tremblay G, et al.
Published: (2019-09-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
by: Goodyear, O, et al.
Published: (2012)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
by: DiNardo, CD, et al.
Published: (2021)

P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON
by: E. N. Oliva, et al.
Published: (2022-06-01)

P586: IADADEMSTAT COMBINATION WITH AZACITIDINE SHOWS ENCOURAGING SAFETY AND EFFICACY DATA IN ELDERLY AND UNFIT AML PATIENTS
by: O. Salamero, et al.
Published: (2022-06-01)

Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy
by: Guanghao Liang, et al.
Published: (2023-08-01)

P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)
by: E. Stein, et al.
Published: (2022-06-01)

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes
by: Garcia-Manero, G, et al.
Published: (2021)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results
by: Daver, NG, et al.
Published: (2022)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
by: Marina Konopleva, et al.
Published: (2023-08-01)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
by: Daver, N, et al.
Published: (2022)

ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
by: Marta E Capala, et al.
Published: (2014-01-01)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
by: Deepak Kumar Shukla, et al.
Published: (2021-01-01)

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results
by: Sallman, D, et al.
Published: (2021)

P412: LOW EXPOSURE, EXTENDED DOSING MIMICKING CLINICAL EXPOSURES OF ORAL AZACITIDINE SYNERGIZES WITH VENETOCLAX IN PRECLINICAL AML MODELS
by: D. Jeyaraju, et al.
Published: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 STUDY OF VENETOCLAX & ORAL AZACITIDINE VS. ORAL AZACITIDINE AS MAINTENANCE THERAPY FOR PTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPHY
by: V. Ivanov, et al.
Published: (2022-06-01)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
by: Wenjian Wei, et al.
Published: (2023-08-01)

Bone Marrow Microenvironment-Induced Chemoprotection in <i>KMT2A</i> Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
by: Kara M. Lehner, et al.
Published: (2023-06-01)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
by: Jun Li, et al.
Published: (2022-12-01)

Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
by: Shakeri S., et al.
Published: (2021-11-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

The Graft-Versus-Leukemia Effect in AML
by: Connor Sweeney, et al.
Published: (2019-11-01)

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes

Similar Items

Similar Items